Oryx
Status and phase
Conditions
Treatments
About
Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.
Full description
Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.
Initially four equal doses of ParvOryx will be administered intravenously on four consecutive days. Seven to fourteen days after the first intravenous administration the drug will be injected directly in a hepatic metastasis of the pancreatic cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
7 participants in 1 patient group
There are currently no registered sites for this trial.
Start date
Dec 01, 2015 • 9 years ago
End date
May 01, 2018 • 6 years ago
Today
Jan 23, 2025
Lead Sponsor
Oryx
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal